Benzinga·2026-01-26 12:52Group 1 - Erasca Inc. is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers [4] - The company is conducting two Phase 1 trials with its lead drug ERAS-0015 in patients with RAS-mutant solid tumors, with initial data expected in 2026 [4] - Erasca recently priced its upsized public offering of 22.5 million shares at $10.00 per share, resulting in gross proceeds of $225 million [4][5] Group 2 - Revolution Medicines is a late-stage clinical oncology company developing targeted therapies for RAS-addicted cancers, with a pipeline that includes RAS(ON) inhibitors [3] - The company was valued at approximately $30 billion during acquisition discussions with Merck, which ultimately ended due to disagreements on valuation [2] - Merck's decision reflects its disciplined approach to deal size despite interest in high-growth oncology assets [2]